The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to sever ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease ...

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second inflammatory bowel disease (IBD) condition, Crohn's disease (“CD”), in the United ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

Indianapolis: Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh ...